Baseline [


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
01 12 2021
Historique:
received: 03 08 2021
accepted: 16 11 2021
entrez: 2 12 2021
pubmed: 3 12 2021
medline: 11 3 2022
Statut: epublish

Résumé

The role and implementation of tau PET imaging for predicting subsequent cognitive decline in Alzheimer's disease (AD) remains uncertain. This study was designed to evaluate the relationship between baseline [ Our analyses incorporated data from 67 participants, including cognitively normal controls (n = 10) and β-amyloid (Aβ)-positive individuals ([ Univariate analyses indicated that greater baseline [ Our results suggest that [

Sections du résumé

BACKGROUND
The role and implementation of tau PET imaging for predicting subsequent cognitive decline in Alzheimer's disease (AD) remains uncertain. This study was designed to evaluate the relationship between baseline [
METHODS
Our analyses incorporated data from 67 participants, including cognitively normal controls (n = 10) and β-amyloid (Aβ)-positive individuals ([
RESULTS
Univariate analyses indicated that greater baseline [
CONCLUSIONS
Our results suggest that [

Identifiants

pubmed: 34852837
doi: 10.1186/s13195-021-00937-x
pii: 10.1186/s13195-021-00937-x
pmc: PMC8638526
doi:

Substances chimiques

Amyloid beta-Peptides 0
tau Proteins 0

Banques de données

ClinicalTrials.gov
['NCT02640092']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

196

Informations de copyright

© 2021. The Author(s).

Références

Brain. 2019 Jan 1;143(1):320-335
pubmed: 31886494
JAMA Neurol. 2019 Aug 1;76(8):915-924
pubmed: 31157827
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Neuron. 2016 Mar 2;89(5):971-982
pubmed: 26938442
JAMA. 2014 Oct 1;312(13):1342-3
pubmed: 25268441
J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9
pubmed: 9845158
Ann Neurol. 2016 Jan;79(1):110-9
pubmed: 26505746
J Nucl Med. 2019 Jan;60(1):107-114
pubmed: 29880509
Int Psychogeriatr. 1997;9 Suppl 1:173-6; discussion 177-8
pubmed: 9447441
Mol Psychiatry. 2019 Aug;24(8):1112-1134
pubmed: 30635637
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Hum Brain Mapp. 2003 Aug;19(4):224-47
pubmed: 12874777
J Nucl Med. 2020 Jun;61(6):911-919
pubmed: 31712323
J Nucl Med. 2012 Mar;53(3):378-84
pubmed: 22331215
JAMA Neurol. 2015 Oct;72(10):1183-90
pubmed: 26280102
Brain. 2019 Jun 1;142(6):1723-1735
pubmed: 31009046
Neurology. 2016 Jul 26;87(4):375-83
pubmed: 27358341
Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13-21
pubmed: 9236948
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Ann Neurol. 2019 Feb;85(2):181-193
pubmed: 30549303
Brain. 2020 May 1;143(5):1588-1602
pubmed: 32380523
Neurobiol Aging. 2019 Sep;81:138-145
pubmed: 31280117
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2077-2089
pubmed: 31254035
Appl Neuropsychol Adult. 2019 May-Jun;26(3):268-274
pubmed: 29319337
Brain. 2019 Oct 1;142(10):3230-3242
pubmed: 31501889
J Alzheimers Dis. 2021 Nov 18;:
pubmed: 34806603
Neurobiol Aging. 1995 May-Jun;16(3):271-8; discussion 278-84
pubmed: 7566337
N Engl J Med. 2010 Jan 28;362(4):329-44
pubmed: 20107219
Clin Neuropsychol. 2015;29(7):905-23
pubmed: 26548428
Neuropsychiatr Dis Treat. 2014 May 24;10:929-52
pubmed: 24926196
NeuroRx. 2004 Apr;1(2):182-8
pubmed: 15717018
Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2155-2164
pubmed: 31915896
J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):171-3
pubmed: 22019547
Dement Geriatr Cogn Disord. 1999 Nov-Dec;10(6):534-40
pubmed: 10559571
Brain. 2020 Feb 1;143(2):650-660
pubmed: 31834365
Neurology. 2018 Aug 28;91(9):e859-e866
pubmed: 30068637
JAMA Neurol. 2021 Aug 1;78(8):961-971
pubmed: 34180956
JAMA. 2019 Jun 18;321(23):2316-2325
pubmed: 31211344
Alzheimers Dement. 2017 Mar;13(3):205-216
pubmed: 27697430
BMC Neurosci. 2010 Sep 16;11:118
pubmed: 20846444
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2295-2305
pubmed: 34041562
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Ann Intern Med. 2008 Mar 4;148(5):370-8
pubmed: 18316755

Auteurs

Edmond Teng (E)

Early Clinical Development, Genentech, Inc., South San Francisco, CA, USA. teng.edmond@gene.com.

Paul T Manser (PT)

Clinical Biostatistics, Genentech, Inc., South San Francisco, CA, USA.

Sandra Sanabria Bohorquez (S)

Clinical Imaging Group, Genentech, Inc., South San Francisco, CA, USA.

Kristin R Wildsmith (KR)

Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.

Karen Pickthorn (K)

Early Clinical Development, Genentech, Inc., South San Francisco, CA, USA.

Suzanne L Baker (SL)

Clinical Imaging Group, Genentech, Inc., South San Francisco, CA, USA.
Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.

Michael Ward (M)

Early Clinical Development, Genentech, Inc., South San Francisco, CA, USA.
Current Address: Alector, Inc., South San Francisco, CA, USA.

Geoffrey A Kerchner (GA)

Early Clinical Development, Genentech, Inc., South San Francisco, CA, USA.
Current Address: F. Hoffmann-La Roche AG, Basel, Switzerland.

Robby M Weimer (RM)

Biomedical Imaging, Genentech, Inc., South San Francisco, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH